Cancure will develop three distinct drug candidates – Genvax platform, lead candidate CNC118; Galectin program, lead candidate CNC225; Mitocans program, lead candidate CNC332 – into Ph2, Ph1, and Ph1 clinical trials, respectively. These technologies are collectively supported by more than 75 peer-reviewed articles in scientific journals and protected by six patent families.
Both Genvax and Galectin enhance the immune response to fight cancer, positioning these programs at the cutting edge of immuno-oncology. Some immuno-oncology drug candidates are now yielding unprecedented patient response rates in late-stage clinical trials. Cancure’s third program, Mitocans, is a targeted therapy that disrupts the energy-producing machinery in the mitochondria of cancer cells to induce metabolic crisis and natural death (apoptosis) of these cells.